ReviewNature reviews. Neurology2018
Advances in meningioma genetics: novel therapeutic opportunities.
Review in Nature reviews. Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05425004 (A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma), which is not on this map. Cited by 126 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Who cites it
126 citing papers in PubMed, 3 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- MRI radiomics in diagnosing high and low grade meningiomas through systematic review and meta analysis.Scientific reports · 2025Pooled it
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- EANO guideline on the diagnosis and management of meningiomas.Neuro-oncology · 2021Guideline
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).Neuro-oncology · 2022Trial
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Lactylation-Driven PROS1-TYRO3-CARF Signaling Promotes Therapy-Induced Senescence Escape and Radioresistance in Meningioma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Efficacy Evaluation of Ultrasound Fusion-Guided Core Needle Biopsy for Infratemporal Fossa Lesions.Head & neck · 2026Article
- Research progress of deep learning based on magnetic resonance imaging in meningioma.Magma (New York, N.Y.) · 2026Review
- Pan-TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity.The journal of pathology. Clinical research · 2026Article
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- Voxel-based spatial distribution of intracranial meningioma subtypes and their relationship to radiogenomic maps.Brain communications · 2026Article
- Novel insights into hypoxia-driven transcriptomic and epigenetic landscapes in grade 3 meningioma.Journal of translational medicine · 2025Article
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.Journal of neuropathology and experimental neurology · 2025Article
- Review
- Article
- Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas.Discover oncology · 2025Article
- Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification.Nature communications · 2025Article
- Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.EBioMedicine · 2025Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas currently are among the most frequent intracranial tumours. Although the majority of meningiomas can be cured by surgical resection, ∼20% of patients have an aggressive clinical course with tumour recurrence or progressive disease, resulting in substantial morbidity and increased mortality of affected patients. During the past 3 years, exciting new data have been published that provide insights into the molecular background of meningiomas and link sites of tumour development with characteristic histopathological and molecular features, opening a new road to novel and promising treatment options for aggressive meningiomas. A growing number of the newly discovered recurrent mutations have been linked to a particular clinicopathological phenotype. Moreover, the updated WHO classification of brain tumours published in 2016 has incorporated some of these molecular findings, setting the stage for the improvement of future therapeutic efforts through the integration of essential molecular findings. Finally, an additional potential classification of meningiomas based on methylation profiling has been launched, which provides clues in the assessment of individual risk of meningioma recurrence. All of these developments are creating new prospects for effective molecularly driven diagnosis and therapy of meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.